Aug 2016 $5 M No. 4 $2 to $10 million 15
Arno Therapeutics, Inc: Raise no. 4, Aug 2016 × Investors in this round 15 investors had bought by the notice of Aug 30, 2016: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alexander Zukiwski, M.D. · Executive Officer, Director Stefan M. Proniuk, Ph.D. · Executive Officer Arie S. Belldegrun, M.D. · Director David M. Tanen · Director Jay F. Moorin · Director Steven B. Ruchefsky · Director Tomer F. Kariv · Director William F. Hamilton, Ph.D. · Director Yacov F. Reizman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes the amount that may be received upon the future exercise of warrants.”Signed by Alexander Zukiwski, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 30, 2016. Read the notice at the SEC .
equity, options SEC Oct 2013 $31 M No. 3 $10 to $50 million 69
Arno Therapeutics, Inc: Raise no. 3, Oct 2013 × Investors in this round 69 investors had bought by the notice of Nov 13, 2013: 69 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $31 M of $31 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alexander R. Zukiwski, M.D. · Executive Officer Glenn R. Mattes · Executive Officer, Director Scott L. Navins · Executive Officer Stefan L. Proniuk, Ph.D. · Executive Officer Arie S. Belldegrun, M.D. · Director David M. Tanen · Director Randy H. Thurman · Director Steven B. Ruchefsky · Director Tomer L. Kariv · Director William F. Hamilton, Ph.D. · Director Yacov L. Reizman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Glenn R. Mattes, President and CEO. Source: SEC Form D, newest notice filed Nov 13, 2013. Read the notice at the SEC .
equity, options SEC Nov 2012 $11 M No. 2 $10 to $50 million 16
Arno Therapeutics, Inc: Raise no. 2, Nov 2012 × Investors in this round 16 investors had bought by the notice of Dec 6, 2012: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $18 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $842,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Alexander R. Zukiwski, M.D. · Executive Officer Glenn R. Mattes · Executive Officer, Director Scott L. Navins · Executive Officer Stefan L. Proniuk, Ph.D. · Executive Officer Arie S. Belldegrun, M.D. · Director David M. Tanen · Director Steven B. Ruchefsky · Director Tomer L. Kariv · Director William F. Hamilton, Ph.D. · Director Yacov L. Reizman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer Maxim Group LLC (CRD 120708) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “In addition to a cash fee of $842,500, warrants to purchase 2,090,000 shares were issued, as well as 60,000 shares and reimbursement for out of pocket expenses up to $30,000.”Signed by David M. Tanen, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Dec 6, 2012. Read the notice at the SEC .
equity, debt, options SEC Sep 2010 $8 M No. 1 $2 to $10 million 24
Arno Therapeutics, Inc: Raise no. 1, Sep 2010 × Investors in this round 24 investors had bought by the notice of Sep 23, 2010: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $13 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $925,750
Finders' fees none
Paid to its own people $669,200 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice David M. Tanen · Executive Officer, Director Arie S. Belldegrun · Director Joshua A. Kazam · Director Peter M. Kash · Director Robert I. Falk · Director William F. Hamilton · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round I-Bankers Securities, Inc. (CRD 41352) · broker-dealer I-Bankers Securities, Inc. (CRD 41352) · Santa Monica, California Sold in CA, CO, CT, DE, FL, GA, IL, MA, MD, MI, NC, NJ, NY, PA, SC, TX, and outside the US Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, New York Sold in AZ, CA, CO, CT, DC, DE, FL, IL, MA, MD, MI, NC, NJ, NY, OH, PA, TN, TX, VA, WA, and outside the US Remarks in the notice On fees: “Max. commission if entire offering is sold. Warrants will also be issued to purchase shares equal to 7% of the aggregate no. of shares sold. Reasonable out-of-pocket expenses and legal fees will be paid.”On the use of proceeds: “Assumes entire offering is sold; Riverbank commissions may be allocated between Messrs. Kash, Kazam and Tanen.”Signed by David M. Tanen, President. Source: SEC Form D, newest notice filed Sep 23, 2010. Read the notice at the SEC .
equity, options SEC